XML 28 R16.htm IDEA: XBRL DOCUMENT
v3.25.1

Financial Assets and Liabilities | 3 Months Ended
--- | ---
Mar. 31, 2025
Subclassifications of assets, liabilities and equities [abstract] |
Financial Assets and Liabilities | Note 10—Financial Assets and Liabilities The financial assets and liabilities comprise the following:
|  | March 31, 2025 |  |  | December 31, 2024 |
|  | (EUR’000) |
Financial assets by category |  |  |  |  |  |
Trade receivables |  |  | 66,685 |  |  |  | 166,280 |
Other receivables (excluding indirect tax receivables) |  |  | 4,501 |  |  |  | 3,964 |
Cash and cash equivalents |  |  | 517,923 |  |  |  | 559,543 |
Financial assets measured at amortized cost |  |  | 589,109 |  |  |  | 729,787 |
Total financial assets |  |  | 589,109 |  |  |  | 729,787 |
Classified in the statement of financial position |  |  |  |  |  |
Non-current assets |  |  | 2,657 |  |  |  | 2,317 |
Current assets |  |  | 586,452 |  |  |  | 727,470 |
Total financial assets |  |  | 589,109 |  |  |  | 729,787 |
Financial liabilities by category |  |  |  |  |  |
Borrowings |  |  |  |  |  |
Convertible senior notes |  |  | 449,562 |  |  |  | 458,207 |
Royalty funding liabilities |  |  | 303,347 |  |  |  | 305,379 |
Lease liabilities |  |  | 94,363 |  |  |  | 93,030 |
Trade payables and accrued expenses |  |  | 84,370 |  |  |  | 96,394 |
Other liabilities (excluding indirect tax, and employee related payables) |  |  | 3,870 |  |  |  | 311 |
Financial liabilities measured at amortized cost |  |  | 935,512 |  |  |  | 953,321 |
Derivative liabilities |  |  | 174,581 |  |  |  | 150,670 |
Financial liabilities measured at fair value through profit or loss |  |  | 174,581 |  |  |  | 150,670 |
Total financial liabilities |  |  | 1,110,093 |  |  |  | 1,103,991 |
Classified in the statement of financial position |  |  |  |  |  |
Non-current liabilities |  |  | 357,312 |  |  |  | 365,080 |
Current liabilities |  |  | 752,781 |  |  |  | 738,911 |
Total financial liabilities |  |  | 1,110,093 |  |  |  | 1,103,991 |
Borrowings Convertible Senior Notes In March 2022, the Company issued an aggregate principal amount of $575.0 million of fixed rate 2.25% convertible notes. The net proceeds from the offering of the convertible notes were $557.9 million (€503.3 million) after deducting the initial purchasers’ discounts and commissions and offering expenses. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on April 1, 2028. The convertible notes accrue interest at a rate of 2.25% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company’s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is 6.0118 ADSs per $1,000 principal amount of convertible notes, which represents an initial conversion price of $166.34 per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company’s option at any time, and from time to time, on or after April 7, 2025, but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. Royalty Funding Liabilities The Company has entered into capped synthetic royalty funding agreements with Royalty Pharma (the “Purchaser”), which is presented as part of borrowings, and represents the Company’s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements. YORVIPATH Agreement In September 2024, the Company entered into a $150.0 million capped synthetic royalty funding agreement (the “Royalty Pharma Yorvipath Agreement”) with the Purchaser. The net proceeds were $148.2 million (€134.2 million) after deducting offering expenses. Under the terms of the Royalty Pharma Yorvipath Agreement, the Company received an upfront payment of $150.0 million (the “Yorvipath Purchase Price”) in exchange for a 3% royalty on net revenue from sales of YORVIPATH in the U.S. (the “Yorvipath Revenue Payments”). The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of 2.0 times, or 1.65 times if the Purchaser receives Yorvipath Revenue Payments in that amount by December 31, 2029. The Royalty Pharma Yorvipath Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to 2.0 times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to September 30, 2028, and the Company has paid the Purchaser, Yorvipath Revenue Payments equal to the Yorvipath Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to 1.65 times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. SKYTROFA Agreement In September 2023, the Company entered into a $150.0 million capped synthetic royalty funding agreement (the “Royalty Pharma Skytrofa Agreement”) with the Purchaser. The net proceeds were $146.3 million (€136.3 million) after deducting offering expenses. Under the terms of the Royalty Pharma Skytrofa Agreement, the Company received an upfront payment of $150.0 million (the “Skytrofa Purchase Price”) in exchange for a 9.15% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on January 1, 2025 (the “Skytrofa Revenue Payments”). The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of 1.925 times, or 1.65 times if the Purchaser receives Skytrofa Revenue Payments in that amount by December 31, 2031. The Royalty Pharma Skytrofa Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to 1.925 times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser, Skytrofa Revenue Payments equal to the Skytrofa Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to 1.65 times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. Derivative Liabilities Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes. Fair value cannot be measured based on quoted prices in active markets or other observable inputs, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company’s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company’s share price (49.7% and 49.6% as of March 31, 2025 and December 31, 2024, respectively). For additional description of fair values, refer to the following section “Fair Value Measurement.” Sensitivity Analysis On March 31, 2025, all other inputs and assumptions held constant, a 10% relative increase in volatility, will increase the fair value of derivative liabilities by approximately €15.0 million and indicates a decrease in profit or loss and equity before tax. Similarly, a 10% relative decrease in volatility indicates the opposite impact. Similarly, on March 31, 2025, all other inputs and assumptions held constant, a 10% increase in the share price, will increase the fair value of derivative liabilities by approximately €35.3 million and indicates a decrease in profit or loss and equity before tax. Similarly, a 10% decrease in the share price indicates the opposite impact. Fair Value Measurement Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value of lease liabilities are not disclosed. Fair value compared to carrying amount of convertible notes, royalty funding liabilities and derivative liabilities, and their level in the fair value hierarchy is summarized in the following table, where: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs for the asset or liability.
|  | March 31, 2025 |  |  | December 31, 2024 |  |  |  |
|  | Carrying amount |  |  | Fair value |  |  | Carrying amount |  |  | Fair value |  |  | Fair value level |
|  | (EUR’000) |  |  | (1-3) |
Convertible senior notes |  |  | 449,562 |  |  |  | 433,666 |  |  |  | 458,207 |  |  |  | 438,288 |  |  |  | 3 |
Royalty funding liabilities |  |  | 303,347 |  |  |  | 308,018 |  |  |  | 305,379 |  |  |  | 305,673 |  |  |  | 3 |
Financial liabilities measured at amortized cost |  |  | 752,909 |  |  |  | 741,684 |  |  |  | 763,586 |  |  |  | 743,961 |  |  |  |
Derivative liabilities |  |  | 174,581 |  |  |  | 174,581 |  |  |  | 150,670 |  |  |  | 150,670 |  |  |  | 3 |
Financial liabilities measured at fair value through profit or loss |  |  | 174,581 |  |  |  | 174,581 |  |  |  | 150,670 |  |  |  | 150,670 |  |  |  |
The following table specifies movements in level 3 fair value measurements:
|  | 2025 |  |  | 2024 |
|  | (EUR’000) |
Derivative liabilities |  |  |  |  |  |
January 1 |  |  | 150,670 |  |  |  | 143,296 |
Remeasurement recognized in finance (income) or expense |  |  | 23,911 |  |  |  | 53,995 |
March 31 |  |  | 174,581 |  |  |  | 197,291 |
Maturity Analysis The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position as of March 31, 2025:
|  | < 1 year |  |  | 1-5 years |  |  | >5 years |  |  | Total contractual cash-flows |  |  | Carrying amount |
|  | (EUR’000) |
Financial liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
March 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Borrowings (excluding lease liabilities) |  |  | 39,585 |  |  |  | 991,636 |  |  |  | — |  |  |  | 1,031,221 |  |  |  | 752,909 |
Lease liabilities |  |  | 15,129 |  |  |  | 57,607 |  |  |  | 35,250 |  |  |  | 107,986 |  |  |  | 94,363 |
Trade payables, accrued expenses and other liabilities |  |  | 88,240 |  |  |  | — |  |  |  | — |  |  |  | 88,240 |  |  |  | 88,240 |
Total financial liabilities |  |  | 142,954 |  |  |  | 1,049,243 |  |  |  | 35,250 |  |  |  | 1,227,447 |  |  |  | 935,512 |
“Borrowings (excluding lease liabilities)” comprise convertible notes and royalty funding liabilities. Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.

X
- Definition The entire disclosure for financial instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2024-01-01 -Section Scope -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfFinancialInstrumentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration